Melatonina

In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin

Curr Cancer Drug Targets. 2010 May;10(3):279-86.
González A, Alvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ, Cos S.
Mlt counteracted the stimulatory effects of estrone sulfate and exert its antitumoral effects by down-re-gulating the sulfatase pathway of the tumoral tissue.
Sulfatase-inhibitory properties of melatonin.

Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin

Breast Cancer Res Treat. 2011 May;127(1):91-8.
Hill SM, Cheng C, Yuan L, Mao L, Jockers R, Dauchy B, Frasch T, Blask DE.
Abstract Mammary tumor growth is associated with old age and diminished levels of MLT and MT1 receptor during old age, resulting in reduced sensitivity to exogenous MLT.
MLT and its MT1 receptor.

Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor alpha (RORalpha) and ERalpha in MCF-7 human breast cancer cells

Steroids. 2010 Dec;75(12):944-51.
Dong C, Yuan L, Dai J, Lai L, Mao L, Xiang S, Rowan B, Hill SM.
Physiologic concentrations of MLT inhibit the individual and combined transcriptional activity of ERalpha by RORalpha1 and E(2).
RORalpha1/E(2).

Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells

J Pineal Res. 2011 Mar;50(2):150-8.
Proietti S, Cucina A, D'Anselmi F, Dinicola S, Pasqualato A, Lisi E, Bizzarri M.
Cytostatic effects triggered by melatonin and D3 are likely related to a complex TGFβ-1-dependent mechanism, involving down-regulation of both MDM2 and Akt-phosphorylation.
p53/MDM2 ratio.

Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway

Breast Cancer Res. 2010;12(6):R107.
Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM.
Mlt (10-9M) exerts an inhibitory effect on breast cancer cell invasion through down-regulation of the p38, and inhibition of MMP-2 and MMP-9.
Proteinase activity of MMP-2 and MMP-9.

Melatonin receptors, melatonin metabolizing enzymes and cyclin D1 in human breast cancer

J Recept Signal Transduct Res. 2011 Apr;31(2):180-7.
Rögelsperger O, Wlcek K, Ekmekcioglu C, Humpeler S, Svoboda M, Königsberg R, Klimpfinger M, Jäger W, Thalhammer T.
The low expression of CYP1A1 or CYP1A2 in breast cancer specimens suggested that melatonin might be involved in cell cycle arrest.
CYP1A1/1A2, SULT1A1/1A3/1E1, cyclin D1.

Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night

J Pineal Res. 2011 Oct;51(3):259-69.
Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, Mao L, Dauchy E, Sauer LA.
Down-regulation of 13-HODE reduces the activation of growth factor pathways supporting cell proliferation and survival.
3-hydroxyoctadecadie-noic acid (13-HODE).

MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect

J Pineal Res. 2011 Oct;51(3):345-52.
Lee SE, Kim SJ, Youn JP, Hwang SY, Park CS, Park YS.
MLT may modulate miRNA and gene expression as an anticancer mechanism in MCF-7 human breast cancer cells.
MicroRNAs (miRNAs).

Pagine

Abbonamento a RSS - Melatonina